Research2 sources
Perioperative Therapy Tops Prostatectomy Alone in High-Risk Prostate Cancer
The Brief · written from 2 sources
- A substudy of the phase III PROTEUS trial, presented at the ESMO congress, tested adding apalutamide and androgen-deprivation therapy before and after radical prostatectomy in high-risk localized prostate cancer.
- The perioperative regimen was compared with prostatectomy alone, and MedPage Today reported that it outperformed surgery alone.
- The findings were published as a letter in the New England Journal of Medicine, Volume 395, Issue 19, pages 1965-1968.
Why it matters
It offers trial evidence on whether combining a hormone-targeting drug with surgery around the operation may improve outcomes for men with high-risk localized prostate cancer, a question that bears directly on treatment decisions.
Who’s affected
- urologists and oncologists treating high-risk localized prostate cancer
- prostate cancer patients and their families
- #prostate cancer
- #apalutamide
- #clinical trial
- #radical prostatectomy
- #androgen deprivation therapy
(MedPage Today) -- Results from a substudy of the phase III PROTEUS trial presented at the European Society for Medical Oncology (ESMO) congress showed that adding apalutamide (Erleada) and androgen-deprivation therapy (ADT) before and after radical...
Timeline
nejm.org
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
Results published in the New England Journal of Medicine (Volume 395, Issue 19)
MedPageToday.com - medical news for physicians
Perioperative Therapy Tops Prostatectomy Alone in High-Risk Prostate Cancer